JLK

JLK EBIT Margin

The EBIT Margin (Operating Margin) of JLK (322510.KQ) as of Nov 3, 2026 is -892.55 %. In the previous year, EBIT Margin (Operating Margin) was -264.01 % — a change of 238.07% (lower).

EBIT Margin

-892.55 %

YoY

238.07%

Last updated:

EBIT Margin (Operating Margin) of JLK is 2024 -892.55 % . EBIT Margin (Operating Margin) of JLK was 2023 -264.01 % . It decreases by 238.07% lower compared to the previous year.

JLK's operating (EBIT) margin stands at -892.5%, down from -167.8% several years earlier.

The JLK EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-3,007.20 KRW
Jan 1, 2018
-1,272.23 KRW
Jan 1, 2019
-4,702.46 KRW
Jan 1, 2020
-167.80 KRW
Jan 1, 2021
-193.58 KRW
Jan 1, 2022
-261.92 KRW
Jan 1, 2023
-264.01 KRW
Jan 1, 2024
-892.55 KRW
The JLK EBIT Margin history
YEAREBIT MarginYoY
-892.55 %+238.07%
-264.01 %+0.80%
-261.92 %+35.30%
-193.58 %+15.37%
-167.80 %-96.43%
-4,702.46 %+269.62%
-1,272.23 %-57.69%
-3,007.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

JLK Stock analysis

What does JLK do? JLK, Inc. generates revenue through AI medical analysis solutions, AI industry and security analysis solutions, and AI medical diagnostic platforms. The company's products include AI medical systems, AI quantitative analysis platforms, and AI remote platforms, which are sold to healthcare providers and medical institutions. The primary customer segments are hospitals and clinics seeking advanced diagnostic tools for brain disease detection. Revenue streams are derived from software licensing and subscription services for these AI-driven diagnostic systems. JLK, Inc. focuses on developing AI-based data-driven diagnostic systems specifically for brain disease detection. The company's AI medical diagnostic platforms are designed to provide accurate and efficient analysis for medical professionals. These platforms are part of the broader suite of AI medical analysis solutions that include AI quantitative analysis and AI remote platforms. The firm's target market includes healthcare facilities requiring cutting-edge technology for neurological diagnostics. The company's software products, such as AI medical systems and AI quantitative analysis platforms, are marketed to healthcare institutions for integration into their diagnostic workflows. Revenue is primarily generated through licensing agreements and recurring subscription fees for access to the AI-driven diagnostic tools. These solutions are positioned as essential for modern healthcare providers aiming to enhance diagnostic accuracy and patient outcomes in brain disease detection. JLK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JLK stock

EBIT Margin (Operating Margin) of JLK is -892.55 % in 2024.

EBIT Margin (Operating Margin) of JLK changed from -264.01 % to -892.55 %, representing a 238.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) JLK since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s JLK with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — JLK

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — JLK